Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.14 USD | +1.23% | -0.99% | +79.74% |
May. 14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
May. 13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.74% | 285M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.32% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals : Receives Chinese Approval for Heterologous Prime-Boost Clinical Trials of COVID-19 DNA Vaccine Candidate